Autoimmune hepatitis arises when the immune system produces autoantibodies that target the liver's own tissue, particularly the liver parenchyma, leading to chronic inflammation and hepatocyte injury. The precise genetic basis underlying susceptibility to AIH is not fully characterized, and no specific causative genes are identified in current curated data for this condition. The development of autoimmunity in AIH is understood to involve a complex interplay of genetic predisposition and environmental factors. Certain infections, drug exposures, and toxic substances have been identified as potential triggers that may initiate or amplify the autoimmune response in susceptible individuals. Because the condition does not follow a straightforward inherited pattern, family members are not automatically at elevated risk in the manner seen with single-gene disorders, though genetic counseling may be informative for families with multiple affected members.

Diagnosing autoimmune hepatitis typically involves a combination of clinical evaluation, laboratory testing, and in many cases liver biopsy. Blood tests play a central role, with findings often including elevated liver enzymes, elevated immunoglobulin G levels, and the presence of characteristic autoantibodies such as antinuclear antibodies and anti-smooth muscle antibodies. Liver biopsy is frequently performed to assess the degree of inflammation and fibrosis and to support the diagnosis. Because many features of AIH overlap with other liver conditions including viral hepatitis, drug-induced liver injury, and other autoimmune liver diseases such as primary biliary cholangitis, a thorough evaluation is required to distinguish AIH from similar presentations. Specialist-based diagnostic scoring systems are used to integrate clinical, laboratory, and histological findings into a confirmed diagnosis. Molecular genetic testing is not part of standard diagnostic evaluation for this condition.

Management of autoimmune hepatitis focuses on suppressing the abnormal immune response to reduce liver inflammation and prevent progression to cirrhosis. Treatment is individualized and is typically guided by a hepatologist or gastroenterologist with expertise in autoimmune liver disease. Currently, no FDA-approved treatments are listed in the curated data for this condition; however, several therapies are under investigation through orphan drug designation pathways, including budesonide, cannabidiol, and naltrexone, among others. These investigational agents have not been approved by the FDA and should be considered as therapies under development rather than established treatments. Individuals should work closely with their healthcare team to determine which management approaches are most appropriate for their specific situation, including any opportunities to participate in clinical trials.

The course of autoimmune hepatitis is variable and depends on factors including disease severity at the time of diagnosis, response to treatment, and the degree of liver fibrosis present. Some individuals achieve sustained remission with appropriate management, while others experience a relapsing and remitting course that requires ongoing therapeutic adjustment. Untreated or inadequately managed AIH can progress to cirrhosis and its associated complications, though early diagnosis and consistent care significantly improve outcomes for many individuals. Quality of life considerations, including fatigue and the demands of long-term medical management, are important aspects of living with this condition. Regular follow-up with a specialist remains essential for monitoring liver health and adjusting care over time.

Autoimmune hepatitis is an active area of clinical investigation, with numerous ongoing clinical trials currently underway exploring new therapeutic approaches. Research efforts include studies examining immunomodulatory agents, gut microbiome interventions, and novel biologic therapies with the goal of achieving more durable remission with fewer side effects. The orphan drug designation pathway has been applied to several candidate therapies, reflecting the recognized need for better treatment options. Individuals interested in participating in clinical research can search ClinicalTrials.gov or speak with their care team about eligibility for specific studies.